Disc Medicine's Bitopertin Approval Delayed, Stock Drops
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy IRON?
Source: stocktwits
Disc Medicine Inc's stock fell by 7.72% as it crossed below the 5-day SMA, reflecting investor concerns following the FDA's delay in approving Bitopertin, now rescheduled for February 10.
The delay in the approval of Bitopertin, which targets Erythropoietic Protoporphyria, is attributed to safety and efficacy concerns raised by the FDA. This postponement has led to a significant drop in stock price, highlighting the market's reaction to the uncertainty surrounding the drug's launch. Additionally, the company has been preparing for commercialization, but this setback may impact its market readiness and investor confidence.
The implications of this delay could be substantial for Disc Medicine, as it not only affects the anticipated revenue from Bitopertin but also raises questions about the company's overall strategy and market position in the competitive biopharmaceutical landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.780
Low
100.00
Averages
120.20
High
154.00
Current: 64.780
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc., raising serious concerns about the company's governance and potential misconduct in securities practices.
- FDA Review Delay: On January 15, 2026, a drug under development by Disc faced a review delay after FDA scientists flagged safety and efficacy concerns, resulting in a 7.84% drop in stock price to $71.04 per share, indicating market apprehension regarding the product's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its New Drug Application, stating that trials did not demonstrate efficacy related to sunlight exposure, leading to a 21.91% decline in stock price to $55.95 per share, reflecting a sharp drop in investor confidence.
- Potential Legal Consequences: The investigation could lead to class action lawsuits against Disc, and if fraud is confirmed, it may have significant implications for the company's financial health and reputation, prompting investors to closely monitor developments.
See More
Disc Medicine Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could significantly impact the company's reputation and stock price.
- FDA Review Delay: On January 15, 2026, Disc's drug faced a review delay after FDA scientists flagged safety and efficacy concerns, causing the stock price to drop by 7.84% to close at $71.04 per share, reflecting market apprehension about the company's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its New Drug Application, stating that trials did not demonstrate efficacy related to sunlight exposure, leading to a 21.91% stock price decline to $55.95 per share, indicating a loss of investor confidence in the company's future.
- Potential Legal Consequences: Pomerantz LLP, a prominent firm in securities class action litigation, suggests that if fraud is confirmed, Disc may face substantial damages and legal liabilities, further affecting its market performance and investor trust.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact the company's market reputation.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties, which led to a 22% drop in the company's stock price on that day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to participate without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights and potentially providing compensation opportunities for affected shareholders.
- Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its leadership position in the industry and strong support capabilities for investors.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of materially misleading business information, indicating significant legal risks that could undermine investor confidence.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and causing the stock price to plummet by 22% on the same day, directly impacting the value of investors' assets.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Disc Medicine, allowing affected investors to seek compensation without upfront fees, which could provide legal support and help recover some losses for investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record in securities litigation, thereby enhancing investor trust in their representation.
See More
Rosen Law Firm Investigates Potential Securities Claims Against Disc Medicine
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may entitle shareholders to compensation if they purchased the company's securities.
- FDA Response Letter Impact: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, stating that it could not approve the new drug application due to uncertainties requiring additional evidence, resulting in a 22% drop in the company's stock price on that day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no out-of-pocket fees or costs for participants through a contingency fee arrangement, making it accessible for affected shareholders.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its successful track record and resource advantages in this field.
See More
Disc Medicine Under Investigation for Possible Securities Fraud
- Stock Price Plunge: Disc Medicine's stock price plummeted by $15.70, or 21.91%, to close at $55.95 on February 13, 2026, inflicting significant losses on investors and reflecting extreme market pessimism regarding the company's future prospects.
- FDA Rejection: The U.S. FDA issued a Complete Response Letter for the New Drug Application of bitopertin on February 13, 2026, stating that clinical trials failed to demonstrate the drug's efficacy, leading to a collapse in investor confidence and a sharp decline in stock value.
- Regulatory Issues Intensify: Between January and February 2026, Disc Medicine faced a series of adverse regulatory disclosures, with the FDA indicating that clinical data did not meet approval standards, further exacerbating market concerns about the company's future.
- Legal Action Initiated: The Portnoy Law Firm has launched an investigation into Disc Medicine and may file a class action on behalf of investors, highlighting the urgent need for legal recourse due to corporate wrongdoing that has caused significant financial harm.
See More
Disc Medicine Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc., raising serious concerns about the company's governance and potential misconduct in securities practices.
- FDA Review Delay: On January 15, 2026, a drug under development by Disc faced a review delay after FDA scientists flagged safety and efficacy concerns, resulting in a 7.84% drop in stock price to $71.04 per share, indicating market apprehension regarding the product's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its New Drug Application, stating that trials did not demonstrate efficacy related to sunlight exposure, leading to a 21.91% decline in stock price to $55.95 per share, reflecting a sharp drop in investor confidence.
- Potential Legal Consequences: The investigation could lead to class action lawsuits against Disc, and if fraud is confirmed, it may have significant implications for the company's financial health and reputation, prompting investors to closely monitor developments.
See More
Disc Medicine Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Disc Medicine, Inc. investors regarding potential securities fraud or unlawful business practices by the company and its executives, which could significantly impact the company's reputation and stock price.
- FDA Review Delay: On January 15, 2026, Disc's drug faced a review delay after FDA scientists flagged safety and efficacy concerns, causing the stock price to drop by 7.84% to close at $71.04 per share, reflecting market apprehension about the company's prospects.
- New Drug Application Rejection: On February 13, 2026, Disc announced that the FDA issued a Complete Response Letter for its New Drug Application, stating that trials did not demonstrate efficacy related to sunlight exposure, leading to a 21.91% stock price decline to $55.95 per share, indicating a loss of investor confidence in the company's future.
- Potential Legal Consequences: Pomerantz LLP, a prominent firm in securities class action litigation, suggests that if fraud is confirmed, Disc may face substantial damages and legal liabilities, further affecting its market performance and investor trust.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing misleading business information, indicating significant legal risks that could impact the company's market reputation.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties, which led to a 22% drop in the company's stock price on that day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to participate without any out-of-pocket costs, demonstrating the firm's commitment to protecting investor rights and potentially providing compensation opportunities for affected shareholders.
- Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, highlighting its leadership position in the industry and strong support capabilities for investors.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of materially misleading business information, indicating significant legal risks that could undermine investor confidence.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application and causing the stock price to plummet by 22% on the same day, directly impacting the value of investors' assets.
- Class Action Preparation: The Rosen Law Firm is preparing a class action against Disc Medicine, allowing affected investors to seek compensation without upfront fees, which could provide legal support and help recover some losses for investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record in securities litigation, thereby enhancing investor trust in their representation.
See More
Rosen Law Firm Investigates Potential Securities Claims Against Disc Medicine
- Securities Claims Investigation: Rosen Law Firm has announced an investigation into Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may entitle shareholders to compensation if they purchased the company's securities.
- FDA Response Letter Impact: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, stating that it could not approve the new drug application due to uncertainties requiring additional evidence, resulting in a 22% drop in the company's stock price on that day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no out-of-pocket fees or costs for participants through a contingency fee arrangement, making it accessible for affected shareholders.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its successful track record and resource advantages in this field.
See More
Disc Medicine Under Investigation for Possible Securities Fraud
- Stock Price Plunge: Disc Medicine's stock price plummeted by $15.70, or 21.91%, to close at $55.95 on February 13, 2026, inflicting significant losses on investors and reflecting extreme market pessimism regarding the company's future prospects.
- FDA Rejection: The U.S. FDA issued a Complete Response Letter for the New Drug Application of bitopertin on February 13, 2026, stating that clinical trials failed to demonstrate the drug's efficacy, leading to a collapse in investor confidence and a sharp decline in stock value.
- Regulatory Issues Intensify: Between January and February 2026, Disc Medicine faced a series of adverse regulatory disclosures, with the FDA indicating that clinical data did not meet approval standards, further exacerbating market concerns about the company's future.
- Legal Action Initiated: The Portnoy Law Firm has launched an investigation into Disc Medicine and may file a class action on behalf of investors, highlighting the urgent need for legal recourse due to corporate wrongdoing that has caused significant financial harm.
See More
